Madrigal Pharmaceuticals, Inc. (MDGL)
|Net Income (ttm)||-170.86M|
|Trading Day||January 15|
|Day's Range||108.61 - 115.93|
|52-Week Range||60.13 - 133.70|
In November, Madrigal released open label data from the MAESTRO-NAFLD study. This data was positive, and could be used to make predictions about the entire study.
Madrigal Pharmaceuticals Highlights Presentations at The Liver Meeting Digital Experience™, The American Association for the Study of Liver Diseases Meeting November 13, 2020, Including NASH Expert Insights on the Ongoing Open Label Arm of Resmetirom 52-Week Phase 3 MAESTRO-NAFLD-1 Trial
CONSHOHOCKEN, Pa., Nov. 13, 2020 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), announced that Dr. Stephen Harrison, M.D., Medical Director for Pinnacle Clinical Research, S...
Madrigal Pharmaceuticals Announces Completion of Enrollment in Phase 3 MAESTRO NAFLD-1 Trial and Reports 2020 Third Quarter Financial Results and Highlights
CONSHOHOCKEN, Pa., Nov. 05, 2020 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) announced today that it completed enrollment in its MAESTRO NAFLD-1 clinical trial of resmetir...
When it comes to extreme wealth creation, few endeavors can compare to being an owner of a small-cap stock that grows large. The post Small-Cap Stocks Have Led Every Bull Market for Decades ap...
Madrigal Pharmaceuticals Announces Three Abstracts Accepted by The Liver Meeting Digital Experience™, The American Association for the Study of Liver Diseases Meeting in November 2020, including Positive Data from Ongoing Open Label Arm of Resmetirom 52 W
CONSHOHOCKEN, Pa., Oct. 01, 2020 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), announced today that, based on data from studies with MGL-3196 (resmetirom), three posters an...
CONSHOHOCKEN, Pa., Sept. 03, 2020 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) announced today that it has already exceeded the originally targeted enrollment of 700 pati...
Madrigal Pharmaceuticals to Present Secondary Analyses of Data from Phase 2 NASH Study of Resmetirom and Symposium at the Digital International Liver Congress™ 2020
CONSHOHOCKEN, Pa., Aug. 26, 2020 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) announced today that on Friday, August 28, 2020 at the Digital International Liver Congress™...
CONSHOHOCKEN, Pa., Aug. 06, 2020 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) today announced its second quarter 2020 financial results and highlights:
These two companies are going after the same target, but which one should you bet on today?
Madrigal Pharmaceuticals sees its Relative Strength Rating enter the 80-plus level. The post Madrigal Pharmaceuticals Clears Key Benchmark, Hitting 80-Plus RS Rating appeared first on Investor...
They have one big thing in common: great growth prospects.
Madrigal's Positive Data, And Other News: The Good, Bad And Ugly Of Biopharma
Madrigal MAESTRO Phase 3 NASH Trials Continue without Protocol Modifications; New Data Demonstrate that Reductions in Liver Fat Achieved by Resmetirom Predict NASH Resolution and Fibrosis Reduction
-- MAESTRO Phase 3 clinical studies proceed, with more flexible allowances in visits and study drug dispensing for enrolled and screened patients at impacted sites, intended to maintain patien...
Madrigal: A Stellar Stock For This Coronavirus Bear Market
The U.S. Food and Drug Administration is scheduled to make decisions on five therapies in the second quarter, and the one that could make the biggest impact on the company and its shares belon...
These companies are developing drugs that target the one of the biggest threats from the obesity epidemic.
Impressive cash position.
Madrigal Pharmaceuticals Inc. (NASDAQ: MDGL) has seen more than its share of volatility over the past year.
Madrigal: Beyond NASH
Madrigal Pharmaceuticals Announces First Patient Dosed in MAESTRO-NAFLD-1, a Second Phase 3 Multi-Center, Double-Blind, Randomized, Placebo-Controlled Study of Resmetirom (MGL-3196) in Patients With Non-Alcoholic Steatohepatitis (NASH) and Presumed NASH (
-- MAESTRO-NAFLD-1 is the second resmetirom Phase 3 clinical trial in patients with NASH and presumed NASH and follows MAESTRO-NASH, a Phase 3 multi-center, double-blind, randomized, placebo-c...
WEST CONSHOHOCKEN, Pa., Dec. 10, 2019 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) (“Madrigal” or the “Company”), a clinical-stage biopharmaceutical company focused on t...
CONSHOHOCKEN, Pa., Dec. 10, 2019 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) (“Madrigal” or the “Company”), a clinical-stage biopharmaceutical company focused on the de...
NASH sees a highly rewarding market with candidates of blockbuster potential. Let us take a look at the hits and misses in this space so far this year.
Madrigal Pharmaceuticals Announces Publication in The Lancet of Positive Phase 2 Results for Resmetirom (MGL-3196) for the Treatment of Non-alcoholic Steatohepatitis (NASH)
Data from this 36-week, multicenter, randomized, double-blind, placebo-controlled Phase 2 clinical trial in patients with NASH:
CONSHOHOCKEN, Pa., Nov. 06, 2019 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) today announced its third quarter 2019 financial results and highlights:
Investors will want to pay attention to what Assembly Biosciences, CymaBay Therapeutics, and Madrigal Pharmaceuticals say about their most promising candidate therapies.
Which of these NASH-oriented biotechs is the better buy?
Madrigal is one of the more prominent NASH-targeted biopharma companies today.
The following securities are falling knives, meaning their share prices have declined more than 59% over the last 52 weeks.
Biotech stocks Intercept Pharmaceuticals and Madrigal Pharmaceuticals were hit Thursday after the Food and Drug Administration cast doubt on a method of evaluating some liver disease drugs.
Medical technology and biotech stocks were ravaged Wednesday on a "Medicare for All" proposal out of Washington and amid rising popularity for presidential candidate Bernie Sanders.
Although possessing huge market opportunities, there is currently no ideal NASH candidate in the late clinical stage.
Liver Therapy Forum weekly digest provides an overview on what’s happening in the NASH landscape in 2019. This week focuses on Madrigal.
Madrigal Pharmaceuticals, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. The company's lead candidate is MGL-3196, an orally administered, small-molecule, liver-directed, thyroid hormone receptor (THR) ß-selective agonist, which is in Phase III clinical trials for the treatment of non-alcoholic steatohepatitis (NASH). It is also developing MGL-3745, a THR-ß-selective small molecule that is in preclinical ... [Read more...]
|Stock Exchange |
|Ticker Symbol |
According to 16 analysts, the average rating for MDGL stock is "Buy." The 12-month stock price forecast is 170.00, which is an increase of 55.91% from the latest price.